MR VERSUS CEUS LI-RADS FOR DISTINGUISHING HEPATOCELLULAR CARCINOMA FROM OTHER HEPATIC MALIGNANCIES IN HIGH-RISK PATIENTS

被引:16
|
作者
Huang, Zhe [1 ]
Zhou, Pingping [1 ]
Li, Shanshan [1 ]
Li, Kaiyan [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Med Ultrasound, Wuhan 430030, Peoples R China
来源
ULTRASOUND IN MEDICINE AND BIOLOGY | 2021年 / 47卷 / 05期
关键词
Magnetic resonance imaging; Contrast-enhanced ultrasonography; Liver Imaging Reporting and Data System; LIVER-LESIONS; SMALL NODULES; CIRRHOSIS; PATTERN;
D O I
10.1016/j.ultrasmedbio.2021.01.020
中图分类号
O42 [声学];
学科分类号
070206 ; 082403 ;
摘要
Distinguishing between other hepatic malignancies (OMs) and hepatocellular carcinoma (HCC) is vital to allow clinicians to determine optimal treatment and assess prognosis in patients at high risk for HCC. This study evaluated the performance of the Liver Imaging Reporting and Data System (LI-RADS) using magnetic resonance imaging (MRI) versus contrast-enhanced ultrasonography (CEUS) for differentiating HCC from OMs in patients at high risk for HCC. This retrospective study consecutively enrolled 106 high-risk patients with HCC and 52 high-risk patients with OMs. Patients underwent both MRI and CEUS, with histologic diagnosis as a reference standard. The diagnostic performance of MR versus CEUS LI-RADS was calculated and compared. The performance of the modified CEUS LI-RADS criteria was also evaluated and compared. Our research found that MRI features significantly differed between patients with OMs and those with HCC (p < 0.05), with sensitivities of 34.6%-69.2% and specificities of 83.0%-95.3% for diagnosing OMs and an LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma sensitivity of 90.4% and specificity of 83.0% for diagnosing OM. CEUS features also significantly differed between patients with OM and HCC (p < 0.05), with sensitivities of 11.5%-96.2% and specificities of 23.6%-100% for diagnosing OMs, and an LR-M sensitivity of 98.1% and specificity of 84.0% for diagnosing OMs. Accuracies of category LR-M did not significantly differ between MR and CEUS LI-RADS (85.4% vs. 88.6%, p = 0.724). After reclassification of category LR-M nodules to category LR-5 if they exhibited clear intratumoral non-enhanced area boundaries and no punched-out appearance before 5 min, accuracy increased from 88.6% to 96.8% for CEUS LR-M and from 84.8% to 91.1% for CEUS LR-5. LR-M accuracies were significantly higher for the modified version of the CEUS LI-RADS than for MR LI-RADS (96.8% vs. 85.4%, respectively, p = 0.04). CEUS LI-RADS and MR LIRADS can effectively be used to distinguish HCC from OMs. In patients at high risk of HCC, performance may be further improved by using a modified CEUS LI-RADS classification system in which category LR-M lesions are considered LR-5 if they have clear intratumoral non-enhanced area boundaries and do not have a punched-out appearance. (C) 2021 World Federation for Ultrasound in Medicine & Biology. All rights reserved.
引用
收藏
页码:1244 / 1252
页数:9
相关论文
共 50 条
  • [31] LIVER IMAGING REPORTING AND DATA SYSTEM (LI-RADS) IN PATIENTS AT HIGH RISK FOR HEPATOCELLULAR CARCINOMA
    McCullar, B. P.
    Appelbaum, A.
    Phillips, J. K.
    Weir, A.
    Waters, B.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2018, 66 (02) : 416 - 416
  • [32] Risk of Hepatocellular Carcinoma in Patients With Indeterminate (LI-RADS 3) Liver Observations
    Arvind, Ashwini
    Joshi, Sagar
    Zaki, Timothy
    Burkholder, Daniel
    Parikh, Neehar D.
    Singal, Amit G.
    North Amer Liver Canc NALC Consortium
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (04) : 1091 - +
  • [33] Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018
    Zou, Xianlun
    Luo, Yan
    Morelli, John N.
    Hu, Xuemei
    Shen, Yaqi
    Hu, Daoyu
    ABDOMINAL RADIOLOGY, 2021, 46 (07) : 3168 - 3178
  • [34] RISK OF PROGRESSION TO HEPATOCELLULAR CARCINOMA IN PATIENTS WITH INDETERMINATE (LI-RADS 3) OBSERVATIONS
    Arvind, Ashwini
    Zaki, Timothy A.
    Yokoo, Takeshi
    Fetzer, David T.
    Browning, Travis
    Rich, Nicole E.
    Marrero, Jorge A.
    Zhu, Hao
    Yopp, Adam
    Hoshida, Yujin
    Gopal, Purva
    Parikh, Neehar D.
    Singal, Amit G.
    GASTROENTEROLOGY, 2021, 160 (06) : S759 - S760
  • [35] Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018
    Xianlun Zou
    Yan Luo
    John N. Morelli
    Xuemei Hu
    Yaqi Shen
    Daoyu Hu
    Abdominal Radiology, 2021, 46 : 3168 - 3178
  • [36] VALUE OF CONTRAST-ENHANCED ULTRASOUND LI-RADS 2017 IN PATIENTS AT HIGH RISK OF HEPATOCELLULAR CARCINOMA: A COMPARISON STUDY WITH CT/MRI LI-RADS
    Ding, Jianmin
    Zhou, Yan
    Jing, Xiang
    HEPATOLOGY, 2020, 72 : 687A - 687A
  • [37] Contrast-enhanced ultrasound for non-invasive diagnosis of hepatocellular carcinoma: A comparison between CEUS LI-RADS and ESCULAP criteria in a large high-risk cohort of patients
    Saviano, A.
    Riccardi, L.
    Zocco, M. A.
    Baumert, T.
    Rapaccini, G. L.
    Pompili, M.
    Gasbarrini, A.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S417 - S418
  • [38] CEUS and CT/MRI LI-RADS in Association With Serum Biomarkers for Differentiation of Combined Hepatocellular-Cholangiocarcinoma From Hepatocellular Carcinoma
    Zhou, Yan
    Yin, Shanshan
    Zhao, Lin
    Zhang, Xiang
    Li, Meng
    Ding, Jianmin
    Yan, Kun
    Jing, Xiang
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [39] RISK OF PROGRESSION TO HEPATOCELLULAR CARCINOMA IN PATIENTS WITH INDETERMINATE (LI-RADS 3) LIVER OBSERVATIONS
    Arvind, Ashwini
    Joshi, Sagar
    Zaki, Timothy
    Burkholder, Daniel A.
    Yokoo, Takeshi
    Fetzer, David
    Browning, Travis
    Rich, Nicole E.
    Marrero, Jorge A.
    Yopp, Adam C.
    Gopal, Purva
    Parikh, Neehar D.
    Singal, Amit G.
    HEPATOLOGY, 2021, 74 : 668A - 669A
  • [40] Hepatocellular Carcinoma and Other Hepatic Malignancies : MR Imaging
    Roth, Christopher G.
    Mitchell, Donald G.
    RADIOLOGIC CLINICS OF NORTH AMERICA, 2014, 52 (04) : 683 - +